首页> 外文期刊>International journal of oncology >The clinical impact of breast scintigraphy acquired with a breast specific γ-camera (BSGC) in the diagnosis of breast cancer: Incremental value versus mammography
【24h】

The clinical impact of breast scintigraphy acquired with a breast specific γ-camera (BSGC) in the diagnosis of breast cancer: Incremental value versus mammography

机译:乳腺特异性γ摄象仪(BSGC)获得的乳腺闪烁显像对乳腺癌的临床影响

获取原文
           

摘要

We investigated the clinical impact of breast scinti-graphy acquired with a breast specific γ-camera (BSGC) in the diagnosis of breast cancer (BC) and assessed its incremental value over mammography (Mx). A consecutive series of 467?patients underwent BSGC scintigraphy for different indications: suspicious lesions on physical examination and/or on US/MRI negative at Mx (BI-RADS 1 or 3), characterization of lesions suspicious at Mx (BI-RADS 4), preoperative staging in lesions highly suggestive of malignancy at Mx (BI-RADS 5). Definitive histopathological findings were obtained in all cases after scintigraphy: 420/467 patients had BC, while 47/467 patients had benign lesions. The scintigraphic data were correlated to Mx BI-RADS category findings and to histology. The incremental value of scintigraphy over Mx was calculated. Scintigraphy was true-positive in 97.1% BC patients, detecting 96.2% of overall tumor foci, including 91.5% of carcinomas ≤10 mm, and it was true-negative in 85.1% of patients with benign lesions. Scintigraphy gave an additional value over Mx in 141/467 cases (30.2%). In particular, scintigraphy ascertained BC missed at Mx in 31 patients with BI-RADS 1 or 3, including 26 patients with heterogeneously/high dense breast (19/26 with tumors ≤10 mm) and detected additional clinically occult ipsilateral or controlateral tumor foci (all <10 mm) or the in situ component sited around invasive tumors in 77 BC patients with BI-RADS 4 or 5, changing surgical management in 18.2% of these cases; moreover, scintigraphy ruled out malignancy in 33 patients with BI-RADS 4. BSGC scintigraphy proved a highly sensitive diagnostic tool, even in small size carcinoma detection, while maintaining a high specificity. The procedure increased both the sensitivity of Mx, especially in dense breast and in multifocal/multicentric disease, and the specificity as well as it better defined local tumor extension, thus guiding the surgeon to a more appropriate surgical treatment.
机译:我们调查了用乳腺特异性γ摄象机(BSGC)获得的乳腺闪烁照相术对乳腺癌(BC)的诊断的临床影响,并评估了其在乳腺摄影(Mx)上的增值。连续467例患者接受了BSGC闪烁显像检查,以适应不同的适应症:体格检查和/或US / MRI在Mx处阴性的可疑病变(BI-RADS 1或3),在Mx处可疑的病变的表征(BI-RADS 4) ,术前分期提示高度提示Mx恶性(BI-RADS 5)。闪烁扫描后所有病例均获得明确的组织病理学发现:420/467例患有BC,而47/467例患有良性病变。闪烁显像数据与Mx BI-RADS类别发现和组织学相关。计算了闪烁显像在Mx上的增量值。闪烁显像在97.1%的BC患者中为真阳性,检出了96.2%的整体肿瘤灶,包括91.5%≤10 mm的癌,在85.1%的良性病变患者中为真阴性。闪烁显像在141/467例中占比Mx高(30.2%)。特别是,闪烁扫描法确定了31例BI-RADS 1或3患者中Mx漏诊的BC,包括26例异质性/高致密性乳腺癌患者(19/26肿瘤≤10mm),并发现了其他临床隐匿的同侧或对照侧肿瘤灶(所有<10 mm)或原位部位位于77例BC BI-RADS 4或5患者中,浸润性肿瘤周围改变了其中18.2%的手术管理;此外,闪烁显像术排除了33例BI-RADS 4患者的恶性肿瘤。BSGC闪烁显像术被证明是一种高度灵敏的诊断工具,即使在小尺寸的癌症检测中,也保持了高特异性。该手术既提高了Mx的敏感性,尤其是在致密的乳房以及多灶性/多中心性疾病中的敏感性,也提高了特异性,并更好地定义了局部肿瘤的扩展,从而指导了外科医生进行更适当的手术治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号